These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22766968)

  • 1. Herpes zoster among persons living with HIV in the current antiretroviral therapy era.
    Blank LJ; Polydefkis MJ; Moore RD; Gebo KA
    J Acquir Immune Defic Syndr; 2012 Oct; 61(2):203-7. PubMed ID: 22766968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era.
    Gebo KA; Kalyani R; Moore RD; Polydefkis MJ
    J Acquir Immune Defic Syndr; 2005 Oct; 40(2):169-74. PubMed ID: 16186734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort.
    Grabar S; Tattevin P; Selinger-Leneman H; de La Blanchardiere A; de Truchis P; Rabaud C; Rey D; Daneluzzi V; Ferret S; Lascaux AS; Hanslik T; Costagliola D; Launay O;
    Clin Infect Dis; 2015 Apr; 60(8):1269-77. PubMed ID: 25601456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herpes zoster in HIV-1-infected patients in the era of highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Hsiao CF; Wang JL; Chen MY; Hsieh SM; Sheng WH; Chang SC
    Int J STD AIDS; 2005 Oct; 16(10):673-6. PubMed ID: 16212714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and risk factors of herpes zoster among hiv-positive patients in the german competence network for HIV/AIDS (KompNet): a cohort study analysis.
    Jansen K; Haastert B; Michalik C; Guignard A; Esser S; Dupke S; Plettenberg A; Skaletz-Rorowski A; Brockmeyer NH
    BMC Infect Dis; 2013 Aug; 13():372. PubMed ID: 23937603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and risk factors of herpes zoster in human immunodeficiency virus-positive patients initiating combination antiretroviral therapy in Taiwan.
    Lee YC; Hung CC; Tsai MS; Zhang JY; Wu PY; Yang SP; Luo YZ; Chang HY; Liu WC; Sun HY; Chang SC
    J Microbiol Immunol Infect; 2018 Feb; 51(1):38-44. PubMed ID: 27329131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and predictors of herpes zoster among antiretroviral therapy-naïve patients initiating HIV treatment in Johannesburg, South Africa.
    Shearer K; Maskew M; Ajayi T; Berhanu R; Majuba P; Sanne I; Fox MP
    Int J Infect Dis; 2014 Jun; 23():56-62. PubMed ID: 24680820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreasing incidence of herpes zoster in the highly active antiretroviral therapy era.
    Moanna A; Rimland D
    Clin Infect Dis; 2013 Jul; 57(1):122-5. PubMed ID: 23487391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Correlates of Herpes Zoster in People Living with HIV on Effective Antiretroviral Therapy.
    Tovar Salazar A; McKhann A; Chen H; Bosch RJ; Weinberg A
    AIDS Res Hum Retroviruses; 2019 Oct; 35(10):890-895. PubMed ID: 31179712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Antiretroviral Therapy on the Risk of Herpes Zoster among Human Immunodeficiency Virus-Infected Individuals in Tanzania.
    Kawai K; Hawkins CA; Hertzmark E; Francis JM; Sando D; Muya AN; Ulenga N; Fawzi WW
    Am J Trop Med Hyg; 2018 Feb; 98(2):396-401. PubMed ID: 29313475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herpes zoster associated with stroke incidence in people living with human immunodeficiency virus: a nested case-control study.
    Ku HC; Wu YL; Yip HT; Hsieh CY; Li CY; Ou HT; Chen YC; Ko NY
    BMC Infect Dis; 2023 Sep; 23(1):636. PubMed ID: 37770849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children.
    Levin MJ; Anderson JP; Seage GR; Williams PL;
    J Acquir Immune Defic Syndr; 2009 Feb; 50(2):182-91. PubMed ID: 19131890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of Herpes Zoster in HIV-Infected Patients Undergoing Antiretroviral Therapy: A Systematic Review and Meta-analysis.
    Ku HC; Tsai YT; Konara-Mudiyanselage SP; Wu YL; Yu T; Ko NY
    J Clin Med; 2021 May; 10(11):. PubMed ID: 34070645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia.
    Friesen KJ; Chateau D; Falk J; Alessi-Severini S; Bugden S
    BMC Infect Dis; 2017 Jan; 17(1):69. PubMed ID: 28086817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012.
    Yanni EA; Ferreira G; Guennec M; El Hahi Y; El Ghachi A; Haguinet F; Espie E; Bianco V
    BMJ Open; 2018 Jun; 8(6):e020528. PubMed ID: 29880565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of herpes zoster in patients with altered immune function.
    Chen SY; Suaya JA; Li Q; Galindo CM; Misurski D; Burstin S; Levin MJ
    Infection; 2014 Apr; 42(2):325-34. PubMed ID: 24214127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genital Herpes Zoster as Possible Indicator of HIV Infection.
    Ljubojević Hadžavdić S; Kovačević M; Skerlev M; Zekan Š
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):337-338. PubMed ID: 30665486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Herpes Zoster in Persons Living with HIV-1 Infection: Viremia and Immunological Defects Are Strong Risk Factors in the Era of Combination Antiretroviral Therapy.
    Erdmann NB; Prentice HA; Bansal A; Wiener HW; Burkholder G; Shrestha S; Tang J
    Front Public Health; 2018; 6():70. PubMed ID: 29594092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpes zoster among HIV-infected patients in the highly active antiretroviral therapy era: Korean HIV cohort study.
    Song JY; Lee JS; Jung HW; Choi HJ; Lee JS; Eom JS; Cheong HJ; Jung MH; Kim WJ
    J Acquir Immune Defic Syndr; 2010 Mar; 53(3):417-8. PubMed ID: 20190589
    [No Abstract]   [Full Text] [Related]  

  • 20. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study.
    Manosuthi W; Mankatitham W; Lueangniyomkul A; Thongyen S; Likanonsakul S; Suwanvattana P; Thawornwan U; Suntisuklappon B; Nilkamhang S; Sungkanuparph S;
    J Acquir Immune Defic Syndr; 2012 Aug; 60(4):377-83. PubMed ID: 22592586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.